First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Selected Advanced And/or Metastatic Solid Tumours

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(3 sites)

Poland

Site, Bydgoszcz, Kuyavian-Pomeranian Voivodeship

Site, Otwock, Masovian Voivodeship

SIte, Warsaw, Masovian Voivodeship